Structured evidence table for Probiotic Gut Barrier Randomized Trial, generated from 3 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Probiotic Gut Barrier Randomized Trial | Moreover, an imbalanced gut microbiota is associated with the toxicity of anticancer therapies. | 3 | Tao Mingyang (2026) | The role of the gut microbiota in radiation enteritis: from mechanistic insights to therapeutic applications |
| Probiotic Gut Barrier Randomized Trial | For instance, the abundance ofandis correlated with increased chemotherapy toxicity in patients with lung cancer, while the abundance ofandis correlated with that in patients with gastrointestinal cancer. | 3 | Tao Mingyang (2026) | The role of the gut microbiota in radiation enteritis: from mechanistic insights to therapeutic applications |
| Probiotic Gut Barrier Randomized Trial | The abundance of., andis correlated with an increased risk of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs), whereas the abundance of.,andis associated with the opposite effect. | 3 | Tao Mingyang (2026) | The role of the gut microbiota in radiation enteritis: from mechanistic insights to therapeutic applications |
| Probiotic Gut Barrier Randomized Trial | 1 2 3 4 5 , 6 7 , 8 9 10 11 12 13 14 15 16 According to global cancer statistics, there were approximately 20 million new cancer cases and nearly 10 million cancer-related deaths worldwide in 2022. | 3 | Tao Mingyang (2026) | The role of the gut microbiota in radiation enteritis: from mechanistic insights to therapeutic applications |
| Probiotic Gut Barrier Randomized Trial | About 1 in 100 children is born with a congenital heart defect, sometimes associated with genetic or chromosomal abnormalities such as Down syndrome. | 4 | Luca Alina-Costina (2026) | The Gut Microbiome in Congenital Heart Disease: Dysbiosis, Intestinal Barrier Injury, and Translational Opportunities Across the Childhood—A Narrative Review |
| Probiotic Gut Barrier Randomized Trial | Risk factors include heavy alcohol use during pregnancy, exposure to certain medications, and maternal viral infections in the first trimester. | 4 | Luca Alina-Costina (2026) | The Gut Microbiome in Congenital Heart Disease: Dysbiosis, Intestinal Barrier Injury, and Translational Opportunities Across the Childhood—A Narrative Review |
| Probiotic Gut Barrier Randomized Trial | In addition, the risk is higher if a parent or sibling has congenital heart disease. | 4 | Luca Alina-Costina (2026) | The Gut Microbiome in Congenital Heart Disease: Dysbiosis, Intestinal Barrier Injury, and Translational Opportunities Across the Childhood—A Narrative Review |
| Probiotic Gut Barrier Randomized Trial | 1 Congenital heart disease (CHD) refers to structural abnormalities of the heart that develop before birth. | 4 | Luca Alina-Costina (2026) | The Gut Microbiome in Congenital Heart Disease: Dysbiosis, Intestinal Barrier Injury, and Translational Opportunities Across the Childhood—A Narrative Review |
| Probiotic Gut Barrier Randomized Trial | Elevated reactive oxygen species (ROS) also play a key role, as increased ROS levels are found in patients with rosacea []. | 4 | Muacevic Alexander (2026) | The Role of Biotics in Rosacea: A Narrative Review |
| Probiotic Gut Barrier Randomized Trial | Mendelian randomization studies have linked certain bacterial taxa, including uncategorized[] andspecies [], to an increased risk of rosacea, while other taxa appear to confer a protective effect []. | 4 | Muacevic Alexander (2026) | The Role of Biotics in Rosacea: A Narrative Review |
| Probiotic Gut Barrier Randomized Trial | Although these studies provide limited mechanistic insight, they strengthen the evidence that microbial composition influences disease risk and expression. | 4 | Muacevic Alexander (2026) | The Role of Biotics in Rosacea: A Narrative Review |
| Probiotic Gut Barrier Randomized Trial | General features of rosacea 1 2 4 Rosacea is a chronic inflammatory skin condition affecting about 5.5% of adults, mainly aged 30-50. | 4 | Muacevic Alexander (2026) | The Role of Biotics in Rosacea: A Narrative Review |
Source documents